# Gaëtan Servais

> Gaëtan Servais is a Series A investor at Noshaq backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Noshaq](https://shizune.co/investors/profile/noshaq-7a35)
- Total investments: 5
- Last investment: Nov 2023
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gaetan-servais-614121201

Gaëtan Servais is a Series A investor at Noshaq focused on Health Care and Biotechnology. Gaëtan Servais is based out of Liège, Walloon Region and is the CEO of Noshaq.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Life Science | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 2 | 40% |
| Germany | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amyl Therapeutics | Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $5.7M | Series A | Nov 07, 2023 |  |
| Ampacimon | Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors. | $10.6M | Series C | Oct 16, 2023 |  |
| Amyl Therapeutics | Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $10.4M | Series A | Jun 03, 2021 |  |
| GeneQuine Biotherapeutics | GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $6.6M | Series A | Feb 15, 2021 |  |
| Ampacimon | Ampacimon develops dynamic line rating systems for transmission and distribution systems operators. Ampacimon’s products address grid infrastructure challenges such as aging assets, transmissions congestion, renewable integration, interconnectors. | $4.4M |  | Aug 26, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Creos Luxembourg](https://shizune.co/investors/profile/creos-luxembourg) — VC Fund, 2 deals together
- [Gesval](https://shizune.co/investors/profile/gesval) — VC Fund, 2 deals together
- [Korys](https://shizune.co/investors/profile/korys) — VC Fund, 2 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 2 deals together
- [Mérieux Equity Partners](https://shizune.co/investors/profile/m%C3%A9rieux-equity-partners) — VC Fund, 2 deals together
- [6K Venture Capital](https://shizune.co/investors/profile/6k-venture-capital) — VC Fund, 1 deal together

## About Noshaq

VC Fund · Liège, Belgium

The province's economic redistribution and development are facilitated by the Noshaq group.

3 contacts available at Noshaq.

| Name | Title | Profile |
| --- | --- | --- |
| Fabian Marcq | COO | https://shizune.co/investors/profile/fabian-marcq |
| Gaëtan Servais | CEO | https://shizune.co/investors/profile/ga%C3%ABtan-servais |
| Hugues Danze | CCO | https://shizune.co/investors/profile/hugues-danze |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gaëtan Servais invest in?

Gaëtan Servais invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gaëtan Servais last invest?

The most recent investment recorded for Gaëtan Servais closed in Nov 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co